Rosti G, Albertazzi L, Ferrante P, Nicoletti P, Morandi P, Bari M, Macchi S, Monti G, Argnani M, Sebastiani L
Medical Oncology Ravenna, Italy.
Ann Oncol. 1995 Dec;6(10):1045-7. doi: 10.1093/oxfordjournals.annonc.a059069.
In an attempt to mobilise peripheral blood progenitor cells (PBPC) from patients with breast cancer, Epirubicin supported with G-CSF was tested. Another aim of the study was also to optimize the procedure so that the number of leukapheresis procedures could be reduced. These cells were subsequently reinfused as hematologic rescue after high-dose chemotherapy programs.
Twenty-nine patients received Epirubicin 150 mg/sqm + G-CSF at the dose of 5 micro/kg/bw s.c. daily, starting 24 hours after chemotherapy. Twelve had metastatic, eight inflammatory or locally advanced disease, and nine were treated in an adjuvant setting.
The median numbers of CD34+ cells and CFU-GM collected were 12.9 x 106/kg/bw and 111.7 x 10(4)/kg/bw, respectively. The mean number of leukapheresis procedures per patient was 1.8 +/- 0.3 (range 1-3), and the mean day of the first procedure was the tenth +/- 1 (range 8-13) after Epirubicin. The minimum required target for one high-dose procedure was collected in a single leukapheresis in 13 patients. Moreover, in 9 cases one procedure was adequate for two high-dose courses (i.e. > or = 10 x 10(6)/kg/bw CD34+ cells). Response to Epirubicin was evaluable in 14/20 cases, with a response rate of 50%.
Epirubicin delivered at 150 mg/sqm is a very effective mobilising agent for breast cancer patients; to ameliorate the response rate other active drug(s) should be added.
为了从乳腺癌患者中动员外周血祖细胞（PBPC），对表柔比星联合粒细胞集落刺激因子（G-CSF）进行了测试。该研究的另一个目的是优化程序，以减少白细胞分离术的次数。这些细胞随后在大剂量化疗方案后作为血液学救援进行回输。
29例患者在化疗后24小时开始接受表柔比星150mg/m² + G-CSF，剂量为5μg/kg/体重，皮下注射，每日一次。12例有转移，8例有炎症或局部晚期疾病，9例接受辅助治疗。
收集的CD34+细胞和CFU-GM的中位数分别为12.9×10⁶/kg/体重和111.7×10⁴/kg/体重。每位患者白细胞分离术的平均次数为1.8±0.3（范围1-3），首次手术的平均天数是表柔比星治疗后的第十天±1（范围8-13）。13例患者在单次白细胞分离术中收集到了一次大剂量手术所需的最低目标细胞数。此外，在9例患者中，一次手术足以满足两个大剂量疗程（即≥10×10⁶/kg/体重的CD34+细胞）。20例中有14例可评估对表柔比星的反应，反应率为50%。
150mg/m²的表柔比星是乳腺癌患者非常有效的动员剂；为提高反应率，应添加其他活性药物。
